XoZymes replaces traditional chemical production methods with an approach that integrates widely available feedstocks like sugar and biomass with advanced enzymes engineered to thrive outside living ...

A recent study published in eLife offers a new perspective on the development of Alzheimer’s disease, suggesting that the ...

AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...

For years, scientists have focused on amyloid beta buildup as the main culprit in Alzheimer’s disease, but a new study suggests the real problem might lie in a stalled protein-cutting process in the ...

McbA efficiently synthesized 16 high-value molecules—including 11 pharmaceuticals—but struggled with certain large or ...

Report Ocean’s recent report provides an accurate and comprehensive research analysis of the “Saudi Arabia Pompe Disease Market” with a primary focus on the present and past market conditions. The ...

Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India ...